天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

ChemicalBook >> journal list >> Journal of Medicinal Chemistry >>article
Journal of Medicinal Chemistry

Journal of Medicinal Chemistry

IF: 6.79
Download PDF

Amantadine in the treatment of Parkinson's disease and other movement disorders.

Published:1 December 2021 DOI: 10.1016/S1474-4422(21)00249-0 PMID: 34678171
Olivier Rascol, Margherita Fabbri, Werner Poewe

Abstract

The efficacy of amantadine in the symptomatic treatment of patients with Parkinson's disease, discovered serendipitously more than 50 years ago, has stood the test of time and the drug is still commonly used by neurologists today. Its pharmacological actions are unique in combining dopaminergic and glutamatergic properties, which account for its dual effect on parkinsonian signs and symptoms and levodopa-induced dyskinesias. Furthermore, amantadine has additional and less well-defined pharmacological effects, including on anticholinergic and serotonergic activity. Evidence from randomised controlled trials over the past 5 years has confirmed the efficacy of amantadine to treat levodopa-induced dyskinesias in patients with Parkinson's disease, and clinical studies have also provided support for its potential to reduce motor fluctuations. Other uses of amantadine, such as in the treatment of drug-induced parkinsonism, atypical parkinsonism, Huntington's disease, or tardive dyskinesia, lack a strong evidence base. Future trials should examine its role in the management of motor and non-motor symptoms in patients with early Parkinson's disease and those with other movement disorders.

Substances (1)

Related products
Procduct Name CAS Molecular Formula Supplier Price
Amantadine 768-94-5 C10H17N 467 suppliers $41.00-$5445.00

Similar articles

IF:0

[Amantadine treatment in Parkinson's disease].

Neural Regeneration Research K Boman, E Kivalo,etc Published: 26 November 1970
IF:98.4

Amantadine in Parkinson's disease.

Neural Regeneration Research P Millac, I Hasan,etc Published: 28 February 1970
IF:3.5

Naringenin: A prospective therapeutic agent for Alzheimer's and Parkinson's disease

Neural Regeneration Research Ahsas Goyal, Aanchal Verma,etc Published: 15 September 2022